Characterisation of adducts of the lipid peroxidation product 4-hydroxy-2-nonenal and amyloid β-peptides by liquid chromatography/electrospray ionisation mass spectrometry

被引:23
作者
Magni, F
Galbusera, C
Tremolada, L
Ferrarese, C
Kienle, MG
机构
[1] IRCCS San Raffaele, Mass Spectrometry Unit, DIBIT, I-20132 Milan, Italy
[2] Univ Milano Bicocca, DIMESAB, Monza, Italy
[3] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy
关键词
D O I
10.1002/rcm.743
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease is characterised by brain neuritic plaques composed of a 39-44 amino acid peptide (Abeta). Lipid peroxidation is an early event induced by these amyloid beta-peptides, leading to the formation of 4-hydroxy-2-nonenal (HNE), which is one of the major end products of this process. HNE has been reported to form adducts via a stable covalent binding to proteins through a Michael addition to amino acid residues with a nucleophilic side chain. The present study reports an investigation of the conditions for formation of Abeta-HNE (Abeta1-28 and Abeta1-42) adducts, and their characterisation by liquid chromatography/electrospray ionisation mass spectrometry (LC/ESI-MS). The results suggest that one or more HNE moieties are localised in the 6-16 region of these adducts, while Asp-1, Lys-16 and Lys-28 are not modified under the described reaction conditions. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1485 / 1493
页数:9
相关论文
共 22 条
[11]   Amyloid-β peptides interact with plasma proteins and erythrocytes:: Implications for their quantitation in plasma [J].
Kuo, YM ;
Kokjohn, TA ;
Kalback, W ;
Luehrs, D ;
Galasko, DR ;
Chevallier, N ;
Koo, EH ;
Emmerling, MR ;
Roher, AE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 268 (03) :750-756
[12]   Biotinylation sites of tumor necrosis factor-α determined by liquid chromatography-mass spectrometry [J].
Magni, F ;
Curnis, F ;
Marazzini, L ;
Colombo, R ;
Sacchi, A ;
Corti, A ;
Kienle, MG .
ANALYTICAL BIOCHEMISTRY, 2001, 298 (02) :181-188
[13]  
MARK RJ, 1995, J NEUROSCI, V15, P6239
[14]  
Mark RJ, 1997, J NEUROCHEM, V68, P255
[15]  
Mayeux R, 1999, ANN NEUROL, V46, P412, DOI 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO
[16]  
2-A
[17]   Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease [J].
Mehta, PD ;
Pirttilä, T ;
Mehta, SP ;
Sersen, EA ;
Aisen, PS ;
Wisniewski, HM .
ARCHIVES OF NEUROLOGY, 2000, 57 (01) :100-105
[18]   4-hydroxynonenal-modified amyloid-β peptide inhibits the proteasome:: possible importance in Alzheimer's disease [J].
Shringarpure, R ;
Grune, T ;
Sitte, N ;
Davies, KJA .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (12) :1802-1809
[19]   EXCESS BRAIN PROTEIN OXIDATION AND ENZYME DYSFUNCTION IN NORMAL AGING AND IN ALZHEIMER-DISEASE [J].
SMITH, CD ;
CARNEY, JM ;
STARKEREED, PE ;
OLIVER, CN ;
STADTMAN, ER ;
FLOYD, RA ;
MARKESBERY, WR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) :10540-10543
[20]  
SZWEDA LI, 1993, J BIOL CHEM, V268, P3342